SCOR IN SYSTEMIC LUPUS ERTHEMATOSUS

当前应用程序请求支持以创建一个专门的中心 北方大学系统性红斑狼疮研究(SCOR) 在教堂山的卡罗莱纳。我们的提案将联合七名调查人员 之前在SLE研究方面有很强的背景(Eisenberg，Clarke博士， 科恩、杜利、福尔克、里夫斯和温菲尔德)在四个项目中 加深对自身抗体免疫调节的认识 在SLE的生产。我们将同时调查人类疾病和小鼠 模型，我们将结合临床研究、细胞 免疫学、免疫化学、免疫遗传学和猪细小病毒的分子生物学 自身抗体和自身抗原。一个行政核心将支持 SCOR的总体指导(主任艾森伯格博士和温菲尔德博士， 助理署长)及提供秘书及会计服务 四个项目。特别委员会将得到以下司的支助 风湿病、多功能关节炎中心和瑟斯顿 关节炎中心，其功能将与 这些现存的实体通过他们的主管温菲尔德博士。这些项目 项目1：MRL/LPR小鼠的抗Sm B细胞。 PI将研究自身抗体基因的免疫遗传学和 小鼠的免疫调节；项目2：“程序性细胞死亡和 全身性自身免疫“科恩博士，派，将调查 自我耐受和自身抗原释放中的细胞凋亡；项目3： “狼疮性肾炎治疗中保留卵巢功能”福尔克博士和 Dooley，共同PIS，将测试化学诱导的暂时性 更年期可预防环磷酰胺的绝育作用 治疗和下调活动期系统性红斑狼疮；以及项目4：“积极反馈 调节自身抗体的产生，“里夫斯博士，派，这将分离 几种自身抗原的基因，并研究这些抗体是如何 蛋白质可以被其他自身抗体诱导。进一步的认识 对自身抗体产生的调控最终将允许 人类系统性红斑狼疮的特效治疗设计。

The current application requests support to create a Specialized Center of Research (SCOR) in Systemic Lupus Erythematosus at the University of North Carolina at Chapel Hill. Our proposal will unite seven investigators with previous strong backgrounds in SLE research (Drs. Eisenberg, Clarke, Cohen, Dooley, Falk, Reeves,and Winfield) in four projects directed at furthering our understanding of the immunoregulation of autoantibody production in SLE. We will investigate both human disease and murine models, and we will combine expertise in clinical research, cellular immunology, immunochemistry, immunogenetics, and the molecular biology of autoantibodies and autoantigens. An administrative core will support the overall direction of the SCOR (Dr. Eisenberg, Director, and Dr. Winfield, Assistant Director) and provide secretarial and accounting services for the four projects. The SCOR will receive support from the Division of Rheumatology, the Multipurpose Arthritis Center, and the Thurston Arthritis Center, and its functions will be efficiently integrated with these existent entities through their director, Dr. Winfield. The projects of the SCOR are: Project 1: Anti-Sm B Cells of MRL/lpr Mice," Dr. Clarke, PI, which will investigate the immunogenetics of autoantibody genes and the immunoregulation of the mice; Project 2: "Programmed Cell Death and Systemic Autoimmunity," Dr. Cohen, PI, which will investigate the role of apoptosis in self tolerance and in the release of autoantigens; Project 3: "Preserving Ovarian Function in Lupus Nephritis Therapy," Drs. Falk and Dooley, co-PIs, which will test whether chemically induced temporary menopause can protect against the sterilizing effects of cyclophosphamide therapy and downregulate active SLE; and Project 4: "Positive Feedback Regulation of Autoantibody Production," Dr. Reeves, PI, which will isolate genes for several autoantigens and investigate how antibodies to such proteins can be induced by other autoantibodies. The further understanding of the regulation of autoantibody production will eventually permit the design of specific therapies in human SLE.